{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"To evaluate the safety of single agent SL-401 in an initial run-in cycle in patients with multiple myeloma","groups":[{"description":"SL-401 7 µg/kg/day in combination with pomalidomide and dexamethasone","id":"OG000","title":"SL-401 7 µg/kg/Day"},{"description":"SL-401 9 µg/kg/day in combination with pomalidomide and dexamethasone","id":"OG001","title":"SL-401 9 µg/kg/Day"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"For a 28-day cycle, Cycle 1","title":"Number of Patients With Dose-limiting Toxicities and Treatment-emergent Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}